샘플 요청 목록

 카트 문의
시장보고서
상품코드
1791808

세계의 아데노 부속 바이러스(AAV) 수탁개발제조기관 시장

Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 455 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 아데노 부속 바이러스(AAV) 수탁개발제조기관 시장은 2030년까지 19억 달러에 이를 전망

2024년에 7억 5,550만 달러로 추정되는 아데노 부속 바이러스(AAV) 수탁개발제조기관 세계 시장은 2024-2030년간 CAGR 16.5%로 성장하여 2030년에는 19억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Downstream 처리 워크플로우는 CAGR 19.4%를 나타내고, 분석 기간 종료까지 12억 달러에 이를 것으로 예측됩니다. Upstream 처리 워크플로우 분야의 성장률은 분석 기간에 CAGR 12.3%로 추정됩니다.

미국 시장은 추정 2억 580만 달러, 중국은 CAGR 22.3%로 성장 예측

미국의 아데노 부속 바이러스(AAV) 수탁개발제조기관 시장은 2024년에 2억 580만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 22.3%로 성장을 지속하여, 2030년에는 4억 2,430만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 11.8%와 15.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.2%를 보일 전망입니다.

세계의 아데노 부속 바이러스(AAV) 수탁개발제조기관 시장 - 주요 동향과 촉진요인 정리

AAV 기반 유전자 치료가 CDMO 서비스 수요를 견인하는 이유는 무엇일까?

AAV 기반 유전자 치료의 채택이 증가하고 있는 것이 바이러스 벡터 생산 전문 개발제조수탁기관(CDMO)의 성장을 가속하는 주요 요인으로 작용하고 있습니다. AAV는 안전성 프로파일, 장기적인 유전자 발현 능력, 희귀 유전질환, 종양학, 신경퇴행성 질환 등 다양한 치료 분야에 적용 가능하여 유전자 치료에 선택되는 벡터로 부상하고 있습니다. 유전자 치료제 후보물질의 세계 파이프라인이 계속 확대됨에 따라, 바이오 제약사들은 전문 지식을 활용하고 시장 출시 시간을 단축하며 규제 준수를 보장하기 위해 전문 CDMO에 AAV 개발 및 제조를 위탁하는 사례가 증가하고 있습니다. 또한, AAV 벡터를 활용한 임상시험이 증가함에 따라 엄격한 품질 기준을 충족하는 확장 가능하고 효율적인 제조 공정에 대한 CDMO의 의존도가 높아지고 있습니다. 업스트림 및 하류 처리 문제를 포함한 AAV 제조의 복잡성으로 인해 전문 지식과 인프라가 필요하기 때문에 생명공학 기업들은 CDMO와 협력하여 제조를 간소화하고 핵심 연구 및 상업화 노력에 집중할 수 있도록 하고 있습니다.

기술 혁신은 어떻게 AAV 제조 능력을 향상시키고 있는가?

바이오프로세스 기술과 제조 플랫폼의 급속한 발전은 AAV 제조에 혁명을 일으켜 CDMO가 고객에게 보다 효율적이고 확장 가능하며 비용 효율적인 솔루션을 제공할 수 있도록 하고 있습니다. CDMO는 현탁 세포 배양 시스템, 고수율 정제 기술, 자동화 주도 바이오 제조 등의 혁신을 통해 AAV 제조의 기존 병목 현상을 극복하고 있습니다. 일회용 바이오리액터와 폐쇄형 시스템 제조의 채택은 유연성을 더욱 높이고 오염 위험을 줄이며 CDMO가 상업적 규모의 생산에 대한 수요 증가에 쉽게 대응할 수 있도록 돕습니다. 또한, 바이오프로세스 최적화에 인공지능(AI)과 머신러닝을 통합하여 수율 예측 가능성과 운영 효율성을 향상시키고 있습니다. AAV 기반 유전자 치료제가 상용화를 향해 나아가고 있는 가운데, CDMO는 제품의 일관성과 규제 준수를 유지하면서 대량 생산을 지원하는 차세대 제조 기술에 많은 투자를 하고 있습니다. 이러한 기술의 발전으로 생산 비용과 납기가 단축되어 바이오 제약 기업은 유전자 치료제를 보다 신속하고 경쟁력 있는 가격으로 시장에 출시할 수 있게 되었습니다.

AAV CDMO 부문에는 어떤 규제적 도전과 시장 기회가 존재합니까?

AAV 기반 유전자 치료제의 규제 환경은 빠르게 진화하고 있으며, 이 분야에서 사업을 전개하는 CDMO에게 과제와 기회를 동시에 창출하고 있습니다. 미국 FDA, 유럽의약품청(EMA) 및 기타 세계 각국의 규제 기관에서 부과하는 엄격한 규제 요건은 엄격한 품질 관리, 공정 검증, 우수의약품 제조 및 품질관리기준(GMP) 준수를 요구하고 있습니다. 이러한 요구사항을 충족하는 것은 바이오제약 기업에게 큰 과제이며, 규제 준수에 대한 깊은 이해를 가진 전문 CDMO에 대한 수요가 증가하고 있습니다. 한편, 규제 당국은 조기 승인 및 희귀질환 치료제 지정을 통해 유전자치료제 개발을 적극 지원하고 있으며, CDMO가 서비스를 확대할 수 있는 새로운 기회를 창출하고 있습니다. 바이오 제조의 투명성과 추적성에 대한 관심이 높아지면서 CDMO는 전자 배치 기록 및 실시간 모니터링 시스템과 같은 디지털 솔루션을 도입하여 컴플라이언스 기준을 충족하고 업무 효율성을 향상시키고 있습니다. 또한, 지정학적 불확실성과 물류의 어려움으로 인해 세계 공급망의 탄력성에 대한 요구가 증가함에 따라, 바이오 제약사들은 멀티사이트 제조 역량과 지리적 다양성을 갖춘 CDMO를 찾고 있습니다.

AAV CDMO 시장의 성장을 가속하는 주요 요인은?

AAV 위탁 개발 및 제조 기관 시장의 성장은 유전자 치료 승인 건수 증가, 상업적 규모의 AAV 생산에 대한 수요 증가, 바이오 제약 기업의 아웃소싱 추세 증가 등 여러 요인에 의해 주도되고 있습니다. 안과, 혈액학, 순환기내과 등 신흥 치료 분야에서 AAV 벡터의 적용이 확대되면서 시장 성장을 더욱 촉진하고 있으며, 기업들은 임상 및 상업적 공급 수요를 지원할 신뢰할 수 있는 제조 파트너를 찾고 있습니다. 또한, 개인 맞춤형 의료 및 표적 유전자 도입 솔루션에 대한 관심이 높아짐에 따라, 틈새 환자군에 대응할 수 있는 유연하고 확장 가능한 제조 플랫폼에 대한 요구가 증가하고 있습니다. 생명공학 연구에 대한 투자 증가와 벤처캐피털 및 정부기관의 자금 유입도 생명공학 스타트업이 대규모 자본 지출 없이 CDMO 서비스를 활용할 수 있게 함으로써 시장 확대에 기여하고 있습니다. 또한, AAV CDMO 시장 내 경쟁 환경은 AAV 기반 유전자 치료에 대한 세계 수요 증가에 대응하기 위해 각 업체들이 역량과 지역적 범위를 강화하기 위해 전략적 제휴, 합병, 인수를 추진하고 있습니다.

부문

워크플로우 유형(Downstream 처리 워크플로우, Upstream 처리 워크플로우), 배양 유형(접착 배양, 현탁배양), 용도(세포 및 유전자 치료 개발 용도, 백신 개발 용도, 바이오의약품 및 Drug Discovery 용도, 바이오메디컬 연구 용도), 최종 용도(제약 및 의약품 기업 최종 용도, 학술기관 및 연구기관 최종 용도)

조사 대상 기업 예

  • Aldevron LLC
  • Biovian Oy
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Esco Aster Pte. Ltd.
  • Genezen, Inc.
  • Oxford Biomedica PLC
  • Porton Advanced
  • ProBio Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.21

Global Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market to Reach US$1.9 Billion by 2030

The global market for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations estimated at US$755.5 Million in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 16.5% over the analysis period 2024-2030. Downstream Processing Workflow, one of the segments analyzed in the report, is expected to record a 19.4% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Upstream Processing Workflow segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$205.8 Million While China is Forecast to Grow at 22.3% CAGR

The Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations market in the U.S. is estimated at US$205.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$424.3 Million by the year 2030 trailing a CAGR of 22.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.8% and 15.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Global Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market - Key Trends & Drivers Summarized

Why Are AAV-Based Gene Therapies Driving Demand for CDMO Services?

The rising adoption of AAV-based gene therapies is a major driver fueling the growth of contract development and manufacturing organizations (CDMOs) specializing in viral vector production. AAV has emerged as the vector of choice for gene therapy due to its safety profile, long-term gene expression capabilities, and broad applicability across a wide range of therapeutic areas, including rare genetic disorders, oncology, and neurodegenerative diseases. As the global pipeline of gene therapy candidates continues to expand, biopharmaceutical companies are increasingly outsourcing AAV development and manufacturing to specialized CDMOs to leverage their expertise, reduce time-to-market, and ensure regulatory compliance. Furthermore, the increasing number of clinical trials utilizing AAV vectors underscores the growing reliance on CDMOs for scalable and efficient production processes that meet stringent quality standards. The complexity of AAV manufacturing, including upstream and downstream processing challenges, necessitates specialized knowledge and infrastructure, prompting biotechnology firms to collaborate with CDMOs to streamline production and focus on core research and commercialization efforts.

How Is Technological Innovation Enhancing AAV Manufacturing Capabilities?

Rapid advancements in bioprocessing technologies and manufacturing platforms are revolutionizing AAV production, allowing CDMOs to offer more efficient, scalable, and cost-effective solutions to their clients. Innovations such as suspension cell culture systems, high-yield purification techniques, and automation-driven biomanufacturing are enabling CDMOs to overcome traditional bottlenecks in AAV production. The adoption of single-use bioreactors and closed-system manufacturing is further enhancing flexibility and reducing contamination risks, making it easier for CDMOs to meet the growing demand for commercial-scale production. Additionally, the integration of artificial intelligence (AI) and machine learning in bioprocess optimization is improving yield predictability and operational efficiency. As AAV-based gene therapies advance toward commercialization, CDMOs are investing heavily in next-generation manufacturing technologies to support high-volume production while maintaining product consistency and regulatory compliance. These technological advancements are helping reduce production costs and turnaround times, enabling biopharmaceutical companies to bring gene therapies to market more rapidly and at competitive pricing.

What Regulatory Challenges and Market Opportunities Exist in the AAV CDMO Sector?

The regulatory landscape for AAV-based gene therapies is evolving rapidly, creating both challenges and opportunities for CDMOs operating in this space. Stringent regulatory requirements imposed by agencies such as the U.S. FDA, European Medicines Agency (EMA), and other global regulatory bodies mandate rigorous quality control, process validation, and compliance with Good Manufacturing Practices (GMP). Meeting these requirements presents a significant challenge for biopharma companies, driving the demand for specialized CDMOs with a deep understanding of regulatory compliance. On the other hand, regulatory agencies are actively supporting the development of gene therapies through accelerated approval pathways and orphan drug designations, creating new opportunities for CDMOs to expand their service offerings. The increasing emphasis on transparency and traceability in biomanufacturing is prompting CDMOs to implement digital solutions, such as electronic batch records and real-time monitoring systems, to meet compliance standards and improve operational efficiency. Additionally, the rising need for global supply chain resilience in light of geopolitical uncertainties and logistical challenges is encouraging biopharma companies to seek CDMOs with multi-site manufacturing capabilities and geographic diversification.

What Are the Key Factors Driving Growth in the AAV CDMO Market?

The growth in the AAV Contract Development and Manufacturing Organizations market is driven by several factors, including the increasing number of gene therapy approvals, rising demand for commercial-scale AAV production, and the growing trend of outsourcing among biopharmaceutical companies. The expanding application of AAV vectors in emerging therapeutic areas such as ophthalmology, hematology, and cardiology is further propelling market growth, as companies seek reliable manufacturing partners to support clinical and commercial supply needs. Moreover, the growing emphasis on personalized medicine and targeted gene delivery solutions is driving the demand for flexible and scalable manufacturing platforms that can cater to niche patient populations. The rising investment in biotechnology research and the influx of funding from venture capital firms and government agencies are also contributing to market expansion by enabling biotech startups to leverage CDMO services without significant capital expenditures. Furthermore, the competitive landscape within the AAV CDMO market is witnessing strategic partnerships, mergers, and acquisitions, as companies seek to strengthen their capabilities and geographic reach to better serve the growing global demand for AAV-based gene therapies.

SCOPE OF STUDY:

The report analyzes the Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Workflow Type (Downstream Processing Workflow, Upstream Processing Workflow); Culture Type (Adherent Culture, Suspension Culture); Application (Cell and Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical and Pharmaceutical Discovery Application, Biomedical Research Application); End-Use (Pharmaceutical and Biopharmaceutical Companies End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Aldevron LLC
  • Biovian Oy
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Esco Aster Pte. Ltd.
  • Genezen, Inc.
  • Oxford Biomedica PLC
  • Porton Advanced
  • ProBio Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Gene Therapies Propels the Growth of AAV CDMOs as Key Enablers of Biopharmaceutical Innovation
    • Expanding Pipeline of Rare Disease Treatments Strengthens the Business Case for AAV Manufacturing Services
    • Increasing FDA Approvals for Gene Therapy Products Drive the Need for Scalable AAV Production Capabilities
    • Technological Advancements in AAV Vector Engineering Enhance Efficiency and Productivity in CDMO Operations
    • Growing Strategic Collaborations Between Biotech Companies and CDMOs Accelerate Market Expansion
    • Rising Outsourcing Trends in Biopharma Strengthen Demand for AAV CDMOs to Reduce Time-to-Market
    • Shift Towards Personalized Medicine Fuels Demand for Flexible and Scalable AAV Manufacturing Solutions
    • Growing Investments in Cell and Gene Therapy Research Drive the Expansion of AAV Manufacturing Capabilities
    • Increasing Demand for High-Purity and High-Titer AAV Vectors Spurs Innovation in Manufacturing Processes
    • Global Expansion of Biopharmaceutical Facilities Strengthens the Market Position of AAV CDMOs
    • The Evolution of Viral Vector Platforms Encourages the Adoption of Next-Generation AAV Technologies
    • Growing Number of Clinical Trials Utilizing AAV Vectors Expands the Market Potential for CDMO Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Downstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Downstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Downstream Processing Workflow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Upstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Upstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Upstream Processing Workflow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharmaceutical & Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pharmaceutical & Biopharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adherent Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adherent Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Adherent Culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Suspension Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Suspension Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Suspension Culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cell & Gene Therapy Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cell & Gene Therapy Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Cell & Gene Therapy Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Vaccine Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Vaccine Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Vaccine Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Biopharmaceutical & Pharmaceutical Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Biopharmaceutical & Pharmaceutical Discovery Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Biomedical Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Biomedical Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Biomedical Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • JAPAN
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • CHINA
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • EUROPE
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • FRANCE
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • GERMANY
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 134: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 183: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 197: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • INDIA
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 209: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 212: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 221: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 245: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 260: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 272: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 284: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 308: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 309: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 323: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 335: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 359: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
  • AFRICA
    • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 383: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제